Revenue of LEQEMBI (Preliminary Basis)

Notice Concerning Change in Major Shareholder

Notice of Revisions to Consolidated Financial Forecasts for the First Half and the Full Year of the Fiscal Year Ending March 31, 2027

Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets

Announcement of Comprehensive Collaboration Agreement for Biosimilars

Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)

CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026)

Santen Announces Change of Major Shareholder

Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R-R KMT2A-Rearranged Acute Leuke

Notice of Approval of Transfer to the Standard Market and Withdrawal of the Plan to Comply with the Prime Market Continued Listing Criteria